News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Andromeda Phase III Trial Costs Weigh on Andromeda Results



8/20/2007 12:54:24 AM

IDB Holding Corp. Ltd. (TASE:IDBH) subsidiary Clal Biotechnology Industries Ltd. (TASE: CBI) today published its financial report for the second quarter of 2007. The company posted a net loss of NIS 10.3 million on NIS 8.1 million revenue. The second quarter loss was almost double the NIS 5.7 million loss for the corresponding quarter.

Read at Globes Online


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES